Objective:

To identify the molecular trigger behind the rare clotting disorder linked to adenovirus-based COVID-19 vaccines.

Key Findings:

• Identified adenoviral core protein VII (pVII) as the likely inciting antigen for VITT.
• Antibodies against pVII matched the anti-PF4 antibody fingerprint seen in VITT.
• Nearly all patients carried the same immunoglobulin light-chain variant with a specific mutation (K31E).
• Reversing the K31E mutation reduced PF4 binding and clot-promoting activity.

Interpretation:

The study reveals that a normal immune response to adenovirus can, in rare cases, mistakenly target PF4, leading to clotting disorders.

Limitations:

• Further studies are needed to assess the safety of modified adenoviral vaccines.
• The rarity of VITT limits the sample size for comprehensive analysis.

Conclusion:

Modifying or removing the adenoviral protein pVII in future vaccines could prevent this rare clotting reaction while maintaining vaccine efficacy.